Thirty-six biotechs priced IPOs in 1Q14, raising over $2.6 billion. That's two thirds as much as the $3.8 billion raised in all of 2013. The 1Q14 IPO class is up a median of 25% from their initial valuations, led by a 157% jump by Auspex Pharmaceuticals Inc. (NASDAQ:ASPX). Auspex's SD-809 is in Phase III testing to treat chorea associated with Huntington's disease. (A) Began trading April 2; (B) Follow-ons of units consisting of stock and warrants are excluded from the postmoney and percentage change calculations because the price per share was